Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Debiopharm International SA
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic hepatitis C viral infection
Plasma HCV RNA level lower limit ≥ 10,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening (no upper limit)
HCV genotype 2 or 3
No previous treatment for hepatitis C infection
You may not be if
Evidence of cirrhosis at the time of screening
Evidence of hepatocellular carcinoma at the time of screening
Any other cause of relevant liver disease other than HCV
Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN)
Clareo Health | Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
